These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31124724)

  • 21. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
    Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
    Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S; Aldinc E; Polydefkis M; Adams D; Coelho T; Ueda M; Hale C; Vest J; Nioi P;
    Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
    Coelho T; Adams D; Conceição I; Waddington-Cruz M; Schmidt HH; Buades J; Campistol J; Berk JL; Polydefkis M; Wang JJ; Chen J; Sweetser MT; Gollob J; Suhr OB
    Orphanet J Rare Dis; 2020 Jul; 15(1):179. PubMed ID: 32641071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
    Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
    N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
    Buxbaum JN
    Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response by Solomon to Letter Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study".
    Solomon SD
    Circulation; 2019 Jul; 140(2):e92-e93. PubMed ID: 31283371
    [No Abstract]   [Full Text] [Related]  

  • 27. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
    Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H
    Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S; Rossello A; Orlandini E
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain.
    Galan L; Gonzalez-Moreno J; Martínez-Sesmero JM; Muñoz-Beamud F; Santos-Rubio MD; Tran D; Lebeau P; Stewart M; Mallaina P; Tarilonte P; Peral C; Rozenbaum MH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):967-973. PubMed ID: 33724140
    [No Abstract]   [Full Text] [Related]  

  • 30. Letter by González-Costello et al Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-mediated Amyloidosis: Analysis of the APOLLO Study".
    González-Costello J; Casasnovas C; Díez-López C
    Circulation; 2019 Jul; 140(2):e90-e91. PubMed ID: 31283374
    [No Abstract]   [Full Text] [Related]  

  • 31. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
    J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
    Schmidt HH; Wixner J; Planté-Bordeneuve V; Muñoz-Beamud F; Lladó L; Gillmore JD; Mazzeo A; Li X; Arum S; Jay PY; Adams D;
    Am J Transplant; 2022 Jun; 22(6):1646-1657. PubMed ID: 35213769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
    Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
    Kristen AV; Ajroud-Driss S; Conceição I; Gorevic P; Kyriakides T; Obici L
    Neurodegener Dis Manag; 2019 Feb; 9(1):5-23. PubMed ID: 30480471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
    Adams D; Cauquil C; Labeyrie C; Beaudonnet G; Algalarrondo V; Théaudin M
    Expert Opin Pharmacother; 2016; 17(6):791-802. PubMed ID: 26800456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation.
    Bulinski C; Discher T; Rutsatz W; Assmus B; Krämer HH
    J Neurol; 2022 Jul; 269(7):3912-3914. PubMed ID: 35124750
    [No Abstract]   [Full Text] [Related]  

  • 39. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Merkies IS
    Neurology; 2013 Apr; 80(15):1444-5. PubMed ID: 23569001
    [No Abstract]   [Full Text] [Related]  

  • 40. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.
    De Bleecker JL; Claeys KG; Delstanche S; Van Parys V; Baets J; Tilleux S; Remiche G
    Acta Neurol Belg; 2023 Jun; 123(3):1029-1037. PubMed ID: 36829087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.